Reported 36,000 tests to clinical customers and 8,200 tests to biopharma customers, an increase of 41% and 24%, respectively Cash, cash equivalents and marketable debt securities were $1B as of December 31. "We are very pleased with the strong finish to 2022 that enabled us to post annual volume growth for both clinical and biopharma above 40%, and believe we are well positioned for continued strong double-digit revenue growth in 2023." said Helmy Eltoukhy, co-founder and co-CEO. "During the fourth quarter we delivered on a long-term ambition with the positive readout of our ECLIPSE trial. We are thrilled with the strong and positive feedback expressed by guideline members, key opinion leaders, and patient advocacy leaders about the performance of the Shield test in the ECLIPSE trial," said AmirAli Talasaz, co-founder and co-CEO. "Fueled by this success, we will expand this test to many other cancer types, including lung cancer, the leading cause of death from cancer."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GH:
- Gordon Haskett wonders if Guardant could be ‘shoehorned’ into Agilent search
- Guardant Health initiated with an Outperform at Scotiabank
- Sell these stocks now, proven algorithm says
- Goldman says Guardant selloff, Exact Science rally an overreaction
- Guardant Health price target raised to $70 from $65 at BofA
